Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) EBITDA Margin (2022 - 2023)

Historic EBITDA Margin for Pasithea Therapeutics (KTTA) over the last 2 years, with Q2 2023 value amounting to 1082.08%.

  • Pasithea Therapeutics' EBITDA Margin rose 188529700.0% to 1082.08% in Q2 2023 from the same period last year, while for Mar 2024 it was 4682.74%, marking a year-over-year decrease of 8381500.0%. This contributed to the annual value of 2862.25% for FY2022, which is 116383600.0% up from last year.
  • Pasithea Therapeutics' EBITDA Margin amounted to 1082.08% in Q2 2023, which was up 188529700.0% from 5935.29% recorded in Q1 2023.
  • Pasithea Therapeutics' EBITDA Margin's 5-year high stood at 5935.29% during Q1 2023, with a 5-year trough of 19935.05% in Q2 2022.